About Kerecis
Kerecis is a Healthcare company based in Isafjordur (Iceland) founded in 2007, and was acquired by Coloplast in July 2023. Fish-skin acellular dermal matrix technology is provided for wound treatments. Kerecis has raised $93.11 million across 14 funding rounds from investors including SVB, Coloplast and European Union. The company has 150 employees. Kerecis has completed 1 acquisition, including Phytoceuticals. Kerecis was last valued at $620 million in July 2022. Its website kerecis.com draws about 26 thousand monthly visits. Kerecis offers products and services including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its legal entity is KERECIS, LLC.
Company details
Founded in 2007 in Isafjordur, Iceland, the company operates in the medical technology sector, focusing on acellular fish-skin grafts. Omega3 technology is utilized in products for chronic wound management, hernia repair, breast reconstruction, and abdominal wall reconstruction. Advantages over human and porcine alternatives include better economics, enhanced clinical outcomes, lower disease transmission risks, and no cultural usage barriers. The domain kerecis.com supports global operations.
Products & Services of Kerecis
Kerecis offers a comprehensive portfolio of products and services, including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield.
Fish skin graft for treating chronic wounds and ulcers.
Combination graft for soft-tissue repair in trauma.
Product for burn wound healing and regeneration.
Guide for applying fish skin in surgical procedures.
Fish skin product for private office wound care.
Solutions for animal wound treatment and healing.
Funding Insights of Kerecis
Kerecis has successfully raised a total of $93.11M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $30 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93.11M
- Total Rounds 14
- Last Round Series D — $30M
- Investors Count 7
Latest 10 of 14 funding rounds of Kerecis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $30M | Debt – Venture | – | – | |
| Jul 2022 | $30M | Series D | $620M | KIRKBI A/S | |
| Jun 2022 | $40M | Series C | – | KIRKBI A/S | – |
| Aug 2020 | Debt – Conventional | – | – | ||
| Aug 2020 | Series C | – | – | – | |
| Jul 2020 | $109,567 | Series C | – | – | – |
| Nov 2019 | $1.05M | Grant | – | – | |
| May 2019 | $16M | Series C | – | – | – |
| May 2018 | $1.5M | Debt – Conventional | – | – | – |
| Jan 2018 | $3M | Series B | – | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2022 | $620M | •••••••• |
Last known valuation $620M (Jul 2022). 8 investors in total: 8 institutional.
Investors in Kerecis
Kerecis has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Coloplast and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
KIRKBI is engaged in building a better future for children. | kirkbi.com | Billund, Denmark | ||
A venture capital fund focused on supporting innovative startups in Iceland. | nyskopun.is | Reykjavík, Iceland | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
A pension fund is operated for Icelandic state employees. | lsr.is | Reykjavík, Iceland | ||
Provides pension funds, loans, and savings services for individuals and employers. | 2004 | lifbru.is | Reykjavik, Iceland | |
| emersoncollective.com | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Medical devices for ostomy, urology, and wound care are manufactured. | 1957 | coloplast.com | Humlebaek, Denmark |
Investor details for Kerecis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kerecis
129 people are tracked at Kerecis (56 in leadership, 73 in team); the tracked headcount is 150.
| Name | Role | Group |
|---|---|---|
Baldur Tumi Baldursson | Co-founder & Medical Director | Leadership |
Christopher Harte | Chief Operating Officer, Global Markets & Technologies | Leadership |
G. Fertram Sigurjonsson | Founder, Chairman, President & CEO | Leadership |
Rob Cruickshank | Dermatology | Mohs Director | Leadership |
Tryggvi Gunnarsson | Director Of Regulatory Affairs | Leadership |
Skuli Magnusson | VP Regulatory, Quality And Clinical Affairs | Leadership |
Daniel Stack | Regenerative Burn, Trauma, & Surgical Director--sc | Leadership |
Rob Tomko | Regenerative Burn, Trauma, Surgical Director | Leadership |
Elyce Frabotta | Regional Clinical Trauma And Burn Director | Leadership |
Mike Cadigan | Chief Financial Officer | Leadership |
Brett Chappell | Regional Business Director | Leadership |
Steve Dibiasio | Chief Sales Officer | Leadership |
Keith Covill | Executive Area Director - Western U.s. | Leadership |
Raz Rasmussen | Director Of Sales - Midsouth | Leadership |
Kyle Thompson | Regional Director | Leadership |
Travis Knight | Clinical Sales Training Director | Leadership |
Al A. Pagliarulo | Director, Strategic Enterprise Accounts - East | Leadership |
Michael Walsh | Director Of Field Reimbursement | Leadership |
Gudmundur Magnus Hermannsson | VP Strategic Projects | Leadership |
Colleen Brennan | Director Of Post Market Clinical Research | Leadership |
109 more people are available in the full profile.
Complete people profiles for Kerecis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kerecis
Kerecis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Phytoceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Wound healing products are manufactured by Phytoceuticals in Switzerland. | phytoceuticals.ch | Adliswil, Switzerland | 2015 | Feb 2019 | •••• |
Complete acquisition details for Kerecis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Kerecis
6 dated milestones of Kerecis across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Kerecis is founded.
- Funding First funding round.
- Acquisition Acquires Phytoceuticals.
- Funding Latest funding round, Series D, of $30.0M.
- Milestone Reaches Minicorn status.
- Exit Acquired by Coloplast.
Web traffic of Kerecis
The website of Kerecis (kerecis.com) receives about 26.1K visits a month.
- Monthly visits26.1K
▲ 91.6% vs previous month
Websites whose visitors overlap most with Kerecis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrials.gov | 100% | 3.3M | #13,034 | View details | |
| woundreference.com | 93% | 15.7K | #1,476,557 | View details | |
| vivex.com | 91% | 7.2K | #3,030,609 | View details | |
| healor.com | 87% | 11.5K | #1,978,831 | View details | |
| organogenesis.com | 86% | 14.8K | #1,257,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Kerecis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kerecis
Complete news archive for Kerecis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kerecis
Kerecis was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Kerecis is headquartered in Isafjordur, Iceland.
Kerecis is a funded company, having raised a total of $93.11M across 14 funding rounds to date. The company's 1st funding round was a Series B of $3M, raised on Jan 2010.
Kerecis has 150 employees.
Founded in 2007 in Isafjordur, Iceland, the company operates in the medical technology sector, focusing on acellular fish-skin grafts. Omega3 technology is utilized in products for chronic wound management, hernia repair, breast reconstruction, and abdominal wall reconstruction. Advantages over human and porcine alternatives include better economics, enhanced clinical outcomes, lower disease transmission risks, and no cultural usage barriers. The domain kerecis.com supports global operations.
Kerecis offers MariGen, SurgiClose, SurgiBind, GraftGuide, and 2 more products and services.
Kerecis has made 1 acquisition, including Phytoceuticals.
Kerecis has 8 investors. Key investors include SVB, Coloplast, European Union, KIRKBI, and LSR.
The valuation of Kerecis is $620M as of Jul 2022.
Kerecis operates through Kerecis, Llc.
Yes. Kerecis was acquired by Coloplast in July 2023.

